Herold, Bluestone et al reported early results from anti-CD3 therapy in the
NEJM 2002. 12 volunteers with newly diagnosed diabetes were found to require
40% less insulin to maintain a healthy blood glucose. However, the effect of
the therapy were tailing off towards the end of 1 year of study. This implied
that the therapy delayed full destruction of the pancreatic 
cells.
There are concerns regarding other effects of anti-CD-3 therapy, particularly in children. There is the potential to impede the bodies response to serious infections.
A further trial on anti-CD3 is underway in europe, but is only recruiting adolescents and adults with newly diagnoses diabetes.
American investigators plan to test the effectiviness of anti-CD3 in people at high risk of developing diabetes.